Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06737952

Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis

This study aims to study the inflammatory response in various forms of arthritis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Arthritis, a significant heald burden is characterized by joint inflammation that severely impacts patients' quality of live. Despite advancements in treatment, many individuals with conditions like rheumatoid arthritis (RA), osteoarthritis (OA), and spondyloarthritis (SpA) do not achieve satisfactory outcomes, underscoring the need for more precise therapeutic strategies.

The project aims to characterize the inflammatory response in various form of arthritis by collecting and analyzing synovial tissue-the connective tissue lining joints. Biopsies will be collected through ultrasound-guided biopsies (UGSB), a minimally invasive and well-tolerated procedure. Presence of immune and stromal cells in the tissue, their interactions, and their relationship to clinical symptoms are characterized by histological and molecular methods. By comparing these features across different forms of arthritis, the study aims to identify molecular pathways and biomarkers that distinguish these diseases and their subtypes. The study hopes to contribute to a broader understanding of arthritis pathophysiology, ultimately translating into novel therapeutic targets and tailored clinical strategies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years
  • Clinically relevant arthritis in one or more joints as assessed by the treating rheumatologist, including RA, SpA, connective tissue disease and OA.

Exclusion criteria

  • Known allergies to local anesthetics
  • Family history of bleeding, history of increased bleeding tendency or prolonged bleeding, current treatment with oral anticoagulants or platelet aggregation inhibitors; Quick < 65%, international normalised ratio (INR) ≥ 1.3, thrombocyte count < 100'000/μl, activated partial thromboplastin time (aPTT) > 37 sec
  • Inability or insufficient knowledge of project language to understand the information given in the informed consent form

Treatment and study plan

Primary outcomes

  1. Grade of synovitis

    Time frame: immediately after collection to study completion, up to 5 years

    assessed by the Krenn score in the hematoxylin and eosin staining (Score 0-3, 0=normal, 3=severe)

  2. classification pathotypes

    Time frame: immediately after collection to study completion, up to 5 years

    immunohistochemical staining with cell type specific markers including CD15, CD68, CD3, CD20, CD138 of the collected tissues from different arthritis subtypes

  3. comparing transcriptomic signature

    Time frame: immediately after collection to study completion, up to 5 years

    single-cell RNA sequencing of collected tissues from different arthritis subtypes to identify disease specific biomarkers.

Study contacts

Contact information is provided by the study sponsor or research team.

Diego Kyburz, Prof. Dr.

CONTACT

[email protected]

+41 61 328 74 81

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Dec 17, 2024
Registry last updated
Apr 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.